title: A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C.
abstract: OBJECTIVE
  This study aimed to identify host single nucleotide polymorphisms (SNPs) that are associated with the efficacy of interferon (IFN) therapy in patients with chronic hepatitis C.
  
  
  METHODS
  We examined whether 116 tagging-SNPs from 13 genes that are involved in type I IFN signaling associate with the outcome of IFN therapy in Japanese case-control groups; the study included 468 sustained responders and 587 nonresponders.
  
  
  RESULTS
  We identified 2 SNPs (rs3792323 [A/T] and rs616589 [G/A]), located in intron 2 of mitogen-activated protein kinase-activated protein kinase 3 (MAPKAPK3) that were associated with the outcome of IFN therapy in patients infected with hepatitis C virus (HCV) genotype 1b (P = 4.6 x 10(-5) and 4.8 x 10(-5), respectively). The 2 SNPs were in strong linkage disequilibrium and multivariate logistic regression analysis showed that rs3792323 is an independent factor associated with the IFN efficacy (genotype 1b; P = .0011). MAPKAPK3 is a kinase involved in the mitogen and stress responses, but the biological significance of MAPKAPK3 in IFN responses is poorly understood. By using an allele-specific transcript quantification assay in liver biopsy, we showed that allele-specific expression of MAPKAPK3 messenger RNA, corresponding to the risk allele for nonresponse, was significantly higher than that of the other allele. Luciferase reporter assay data indicated that overexpression of MAPKAPK3 inhibits IFN-alfa-induced gene transcription via IFN-stimulated response element and IFN-gamma-activated site.
  
  
  CONCLUSIONS
  The SNP rs3792323 in MAPKAPK3 associates with the outcome of IFN therapy in patients with HCV genotype 1b. Our functional analyses indicate that MAPKAPK3 inhibits IFN-alfa-induced antiviral activity.
authors.affiliation: Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN (The Institute of Physical and Chemical Research), Kasumi, Minami-ku, Hiroshima, Japan.
authors.forename: Hironobu
authors.initials: H
authors.lastname: Tsukada
authors.forename: Hidenori
authors.initials: H
authors.lastname: Ochi
authors.forename: Toshiro
authors.initials: T
authors.lastname: Maekawa
authors.forename: Hiromi
authors.initials: H
authors.lastname: Abe
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Fujimoto
authors.forename: Masataka
authors.initials: M
authors.lastname: Tsuge
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Takahashi
authors.forename: Hiromitsu
authors.initials: H
authors.lastname: Kumada
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Kamatani
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Chayama
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D002478:Cells, Cultured; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics / Q000821:virology; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D007370:Interferon Type I; D047908:Intracellular Signaling Peptides and Proteins; C098416:MAP-kinase-activated kinase 3; D017346:Protein Serine-Threonine Kinases